Improved renal and bone safety from FTC/TAF regimen in black adults

Organisation: Position: Deadline Date: Location:

Among HIV-infected, virologically suppressed black adults, emtricitabine/tenofovir alafenamide (FTC/TAF) showed improvements in renal and bone safety compared to emtricitabine/tenofovir disoproxil fumarate (FTC/TDF), according to Dr Jason A Flamm, from Kaiser Permanente, Sacramento, and co-authors in an IDWeek 2017 presentation.

At Week 96, FTC/TAF “demonstrated high rates of virologic suppression, improved bone and renal safety, and small increases in lipids, with no treatment differences in total cholesterol:HDL ratio,” reported Flamm and colleagues. “Efficacy and safety of FTC/TAF in black patients were similar to those in nonblack patients.”

“Given the safety advantage of TAF vs TDF from a renal standpoint, FTC/TAF is an important backbone for black patients living with HIV,” the authors concluded.

The research team performed a 96-week subgroup analysis by race for pre-specified efficacy and post-hoc safety outcomes, using data from a randomized, double-blind, active-controlled study (n=663) in virologically suppressed adults with HIV infection who switched to FTC/TAF from FTC/TDF (n=333) vs. continuing FTC/TDF while taking the same third agent (n=330).

20% of patients identified themselves as black. Baseline viral load, CD4 cell counts, renal laboratory parameters, and bone mineral density (BMD) were similar between the 2 treatment arms for blacks and non-blacks.

At Week 96, virologic success among black patients was 87% for FTC/TAF vs. 88% for FTC/TDF and 89% vs. 90% for non-blacks.

Adverse events leading to study drug discontinuation occurred in 1 (2%) black patient in the FTC/TDF group and 4% of non-black patients (8 patients [3%] in the FTC/TAF group and 3 [1%] in the FTC/TDF group). Adverse events leading to discontinuation included (1 patient each): insomnia/mood alteration, dysphagia, atrial fibrillation, diarrhoea, peripheral oedema, overdose, lymphoma, increased serum creatinine, rectal tenesmus, feeling abnormal/headache, renal tubular disorder, and acquired lipodystrophy/affective disorder.

The renal tubular disorder case involved a non-black patient in the FTC/TDF group. Renal biomarkers at Week 96 demonstrated a difference in the median change in eGFR of 10.1 for FTC/TAF group-patients vs. 4.0mL/min in the TDF/TAF group (P=0.06) among black patients. That difference in median change in eGFR was similar to the 10.0 vs 3.9mL/min changes reported for non-blacks.

Among black patients, median percent-change in urine protein:Cr and urine β2M:Cr were significantly different between those in the FTC/TAF group and the FTC/TDF group (-21.5% vs. 6.3% and -16.6% vs. 26.8%, respectively; P=0.01 and P<0.001).

In general, FTC/TAF showed improvements in renal and bone safety vs. FTC/TDF along with sustained efficacy at Week 96. “These results support switching to FTC/TAF from FTC/TDF for the treatment of HIV-1 infection in Black adults,” concluded Flamm.

Background: Black adults are disproportionately affected by HIV.
Methods: We conducted a 96-week subgroup analysis by race (Black vs. non-Black) for efficacy (pre-specified) and safety (post-hoc) from a randomized, double blind, active-controlled study in virologically suppressed HIV-infected individuals who switched to emtricitabine/tenofovir alafenamide (FTC/TAF) from FTC/tenofovir disoproxil fumarate (FTC/TDF) vs continuing FTC/TDF while remaining on the same third agent.
Results: Of 663 treated patients, 136 (20.5%) self-identified as Black (FTC /TAF n=69, FTC /TDF n=67). Baseline viral load, CD4 counts, renal laboratory parameters, and bone mineral density (BMD) were similar between the two arms within Blacks and non-Blacks. For Blacks, virologic success by FDA snapshot algorithm at week 96: FTC /TAF 87.0% vs. FTC /TDF 88.1%; for non-Blacks 89.0% vs 89.7%. Few participants discontinued study drug due to adverse events in either subgroups (FTC/TAF vs FTC/TDF: Black 0 vs. 1.5%; non-Black, 3.0% vs. 1.1%). In assessment of renal and bone safety using estimated glomerular filtration rate (eGFR), renal biomarkers, and BMD, there were differences between two arms that generally favored FTC/TAF over FTC/TDF (Table). In the overall population, no cases of Fanconi syndrome or proximal renal tubulopathy occurred with FTC/TAF; one FTC/TDF participant discontinued study drug due to proximal tubulopathy.
Conclusion: In virologically suppressed Black adults, FTC/TAF demonstrated improvements in renal and bone safety over FTC/TDF with similar sustained efficacy at week 96. These results support switching to FTC/TAF from FTC/TDF for the treatment of HIV-1 infection in Black adults.

Jason A Flamm, Joseph Gathe, Clifford Kinder, Michael Para, Bruce Rashbaum, Sorana Segal-Maurer, David Shamblaw, Michael Wohlfeiler, Benjamin Young, Christine Zurawski, Martin S Rhee

MPR material
IDWeek abstract

Receive Medical Brief's free weekly e-newsletter

Related Posts

Thank you for subscribing to MedicalBrief

MedicalBrief is Africa’s premier medical news and research weekly newsletter. MedicalBrief is published every Thursday and delivered free of charge by email to over 33 000 health professionals.

Please consider completing the form below. The information you supply is optional and will only be used to compile a demographic profile of our subscribers. Your personal details will never be shared with a third party.

Thank you for taking the time to complete the form.